Cargando…

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

BACKGROUND: Tamoxifen has emerged as a potential management option for gynecomastia and breast pain due to non-steroidal antiandrogens, and it is considered an alternative to surgery or radiotherapy. The objective of this systematic review was to assess the benefits and harms of tamoxifen, in compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunath, Frank, Keck, Bastian, Antes, Gerd, Wullich, Bernd, Meerpohl, Joerg J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464149/ https://www.ncbi.nlm.nih.gov/pubmed/22925442 http://dx.doi.org/10.1186/1741-7015-10-96

Ejemplares similares

Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review
por: Kunath, Frank, et al.
Publicado: (2013)

Do urology journals enforce trial registration? A cross-sectional study of published trials
por: Kunath, Frank, et al.
Publicado: (2011)

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
por: Kunath, Frank, et al.
Publicado: (2015)

Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov
por: Kunath, Frank, et al.
Publicado: (2013)

Scientific Value of Systematic Reviews: Survey of Editors of Core Clinical Journals
por: Meerpohl, Joerg J., et al.
Publicado: (2012)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

Correction: Scientific Value of Systematic Reviews: Survey of Editors of Core Clinical Journals
por: Meerpohl, Joerg J., et al.
Publicado: (2012)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
por: Yekedüz, Emre, et al.
Publicado: (2021)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Are pediatric Open Access journals promoting good publication practice? An analysis of author instructions
por: Meerpohl, Joerg J, et al.
Publicado: (2011)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants – In vivo evidence
por: Özten-Kandaş, Nur, et al.
Publicado: (2011)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
por: Flaig, Thomas W., et al.
Publicado: (2017)

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer
por: Nowakowska, Malgorzata K., et al.
Publicado: (2021)

Role of prostate cancer stem-like cells in the development of antiandrogen resistance
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles
por: Blümle, Anette, et al.
Publicado: (2011)

Specialist palliative care services for adults with advanced, incurable illness in hospital, hospice, or community settings—protocol for a systematic review
por: Gaertner, Jan, et al.
Publicado: (2015)

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
por: Zhang, Zeda, et al.
Publicado: (2020)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
por: Ottman, Richard, et al.
Publicado: (2014)

Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment
por: Ivachtchenko, Alexandre V., et al.
Publicado: (2014)

Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
por: Brooke, Greg N., et al.
Publicado: (2015)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism
por: Gheorghe, Andrei Cristian Dan, et al.
Publicado: (2020)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
por: Pinto, Francesco, et al.
Publicado: (2022)

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia
por: Leidinger, Petra, et al.
Publicado: (2015)

A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
por: Freeman, S. N., et al.
Publicado: (1989)

Advantage of soybean isoflavone as antiandrogen on acne vulgaris
por: Riyanto, Puguh, et al.
Publicado: (2015)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer
por: Ghadjar, Pirus, et al.
Publicado: (2020)

Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis
por: Gaertner, Jan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0gm2q0bi9l9itop383oeqqagtv